An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials

被引:20
作者
Bajard, Agathe [1 ]
Chabaud, Sylvie [1 ]
Cornu, Catherine [2 ,3 ,4 ]
Castellan, Anne-Charlotte [4 ]
Malik, Salma [2 ,3 ,4 ]
Kurbatova, Polina [3 ,5 ]
Volpert, Vitaly [5 ]
Eymard, Nathalie [5 ]
Kassai, Behrouz [2 ,3 ,4 ]
Nony, Patrice [2 ,3 ]
机构
[1] Ctr Lutte Canc Leon Berard, Unite Biostat & Evaluat Therapeut, F-69373 Lyon, France
[2] CHU Lyon, Serv Pharmacol Clin, Lyon, France
[3] Univ Lyon 1, CNRS, UMR 5558, F-69365 Lyon, France
[4] Hop Louis Pradel, Ctr Invest Clin & Essais Therapeut, INSERM, CIC1407, Bron, France
[5] Univ Lyon 1, Inst Camille Jordan, UMR 5208, F-69622 Villeurbanne, France
关键词
Randomized controlled clinical trial; Simulation; Modeling; Experimental design; Statistical analysis; Therapeutic evaluation; SINGLE-SUBJECT DESIGNS; SUMATRIPTAN; EFFICACY; THERAPY; SAFETY;
D O I
10.1016/j.jclinepi.2015.06.024
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: The main objective of our work was to compare different randomized clinical trial (RCT) experimental designs in terms of power, accuracy of the estimation of treatment effect, and number of patients receiving active treatment using in silico simulations. Study Design and Setting: A virtual population of patients was simulated and randomized in potential clinical trials. Treatment effect was modeled using a dose-effect relation for quantitative or qualitative outcomes. Different experimental designs were considered, and performances between designs were compared. One thousand clinical trials were simulated for each design based on an example of modeled disease. Results: According to simulation results, the number of patients needed to reach 80% power was 50 for crossover, 60 for parallel or randomized withdrawal, 65 for drop the loser (DL), and 70 for early escape or play the winner (PW). For a given sample size, each design had its own advantage: low duration (parallel, early escape), high statistical power and precision (crossover), and higher number of patients receiving the active treatment (PW and DL). Conclusion: Our approach can help to identify the best experimental design, population, and outcome for future RCTs. This may be particularly useful for drug development in rare diseases, theragnostic approaches, or personalized medicine. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:125 / 136
页数:12
相关论文
共 24 条
  • [1] [Anonymous], 2002, J WILEY
  • [2] Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach
    Bajard, Agathe
    Chabaud, Sylvie
    Perol, David
    Boissel, Jean-Pierre
    Nony, Patrice
    [J]. CONTEMPORARY CLINICAL TRIALS, 2009, 30 (05) : 400 - 410
  • [3] Compliance-guided therapy - A new insight into the potential role of clinical pharmacologists
    Blesius, A
    Chabaud, S
    Cucherat, M
    Mismetti, P
    Boissel, JP
    Nony, P
    [J]. CLINICAL PHARMACOKINETICS, 2006, 45 (01) : 95 - 104
  • [4] Modelling methodology in physiopathology
    Boissel, Jean-Pierre
    Ribba, Benjamin
    Grenier, Emmanuel
    Chapuisat, Guillemette
    Dronne, Marie-Aimee
    [J]. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2008, 97 (01) : 28 - 39
  • [5] New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear
    Boissel, Jean-Pierre
    Cucherat, Michel
    Nony, Patrice
    Chabaud, Sylvie
    Gueyffier, Francois
    Wright, James M.
    Lievre, Michel
    Leizorovicz, Alain
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2008, 61 (03) : 301 - 307
  • [6] Buyse M, 2011, EXPERT REV MOL DIAGN, V11, P171, DOI [10.1586/erm.10.120, 10.1586/ERM.10.120]
  • [7] Statistical comparison of four effect sizes for single-subject designs
    Campbell, JM
    [J]. BEHAVIOR MODIFICATION, 2004, 28 (02) : 234 - 246
  • [8] Experimental designs for small randomised clinical trials: an algorithm for choice
    Cornu, Catherine
    Kassai, Behrouz
    Fisch, Roland
    Chiron, Catherine
    Alberti, Corinne
    Guerrini, Renzo
    Rosati, Anna
    Pons, Gerard
    Tiddens, Harm
    Chabaud, Sylvie
    Caudri, Daan
    Ballot, Clement
    Kurbatova, Polina
    Castellan, Anne-Charlotte
    Bajard, Agathe
    Nony, Patrice
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2013, 8
  • [9] EDWARDS C, 1991, EUR NEUROL, V31, P300
  • [10] Single-subject designs
    Gliner, JA
    Morgan, GA
    Harmon, RJ
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2000, 39 (10) : 1327 - 1329